Hyperion Therapeutics Announces The Publication Of Phase 2 Results Of Glycerol Phenylbutyrate (GPB) For The Treatment Of Hepatic Encephalopathy In Hepatology
2/25/2014 9:06:36 AM
BRISBANE, Calif., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the March 2014 issue of Hepatology. The study met its primary endpoint with significantly fewer patients treated with GPB experiencing HE events as compared to patients receiving placebo.
Help employers find you! Check out all the jobs and post your resume.
comments powered by